Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.78 |
| ▸ | CDK2 | P24941 | 20/20 | 0.78 |
| ▸ | CDK6 | Q00534 | 20/20 | 0.78 |
| ▸ | CDK1 | P06493 | 9/20 | 0.77 |
| ▸ | CDK7 | P50613 | 9/20 | 0.77 |
| ▸ | CDK9 | P50750 | 9/20 | 0.77 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.77 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.77 |
| ▸ | CCND3 | P30281 | 4/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19089122 | 0.88 | CDK4 (1.00) | CDK4CDK2CDK6CDK1CDK7 | |
| SCHEMBL19089039 | 0.87 | CDK4 (1.00) | CDK4CDK2CDK6CDK1CDK7 | |
| SCHEMBL29839750 | 0.87 | CDK4 (1.00) | CDK4CDK2CDK6CDK1CDK7 | |
| SCHEMBL19089131 | 0.87 | CDK4 (1.00) | CDK4CDK2CDK6CDK1CDK7 | |
| SCHEMBL19089158 | 0.86 | CDK4 (1.00) | CDK4CDK2CDK6CDK1CDK7 | |
| SCHEMBL20548963 | 0.86 | CDK4 (0.83) | CDK4CDK2CDK6CDK1CDK7 | |
| SCHEMBL19089040 | 0.85 | CDK4 (1.00) | CDK4CDK2CDK6CDK1CDK7 | |
| SCHEMBL22280761 | 0.85 | CDK4 (1.00) | CDK4CDK2CDK6CDK1CDK7 | |
| SCHEMBL19089100 | 0.85 | CDK4 (1.00) | CDK4CDK2CDK6CDK1CDK7 | |
| SCHEMBL31066313 | 0.85 | CDK4 (0.80) | CDK4CDK2CDK6CDK1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988476-B2 | Substituted pyrimidines as cyclin-dependent kinase inhibitors | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| US-20200239470-A1 | Substituted Pyrimidine Compound for Treating Cancer | SHANGHAI PHARMACEUTICALS HOLDING CO LTD (CN) | 2020-07-30 | — | — | US | disclosed |
| US-10662186-B2 | Substituted pyrimidines as cyclin-dependent kinase inhibitors | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239470-A1 | Substituted Pyrimidine Compound for Treating Cancer | DPYD, TYMP, TYMS | CDK4 93/4885CDK2 112/4885CDK6 129/4885 |
| US-10662186-B2 | Substituted pyrimidines as cyclin-dependent kinase inhibitors | CDK6, CDK4, CCNI | CDK4 2/4885CDK2 6/4885CDK6 1/4885 |
| US-10988476-B2 | Substituted pyrimidines as cyclin-dependent kinase inhibitors | CDK1, CCNI, CDK2 | CDK4 5/4885CDK2 3/4885CDK6 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.